| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Omesh Goyal, Rishi Chowdhary, Tanisha Sehgal, Tanvi Joshi, Akshit Bhambri, Insiya Mohammed Rampurawala, Gurmanleen Singh Sohi, Arghadip Das, Kirti Arora, Ashita Rukmini Vuthaluru and Manjeet Kumar Goyal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Manjeet Kumar Goyal, Department of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, Ohio, USA, 1, Akron General Avenue, AKron, Akron, OH 44308, United States. manjeetgoyal@gmail.com |
| Key Words |
Gastrointestinal motility disorders; Prokinetic agents; Gastroparesis; Dyspepsia; Constipation; Disorders of gut brain interaction; Functional gastrointestinal disorders; Enteric nervous system; Serotonin receptor agonists; Dopamine antagonists; Ghrelin |
| Core Tip |
Prokinetic therapy has long been constrained by modest efficacy, tachyphylaxis, and significant cardiovascular and neurological safety concerns, limiting sustained clinical benefit in gastrointestinal motility disorders. This review redefines prokinetic treatment through an integrated pathophysiological framework that extends beyond traditional neuro-centric models to encompass enteric neurobiology, smooth muscle signalling, interstitial cells of Cajal, gut-brain axis modulation, and hormonal regulation. Emerging agents such as selective 5-hydroxytryptamine type 4 agonists, motilin and ghrelin receptor agonists, sodium/hydrogen exchanger-3 inhibitors, and neuromodulatory approaches, which offer improved mechanistic precision and safety. A phenotype-driven, precision-medicine strategy is essential to optimize therapeutic outcomes and guide future drug development in motility disorders. |
| Publish Date |
2026-05-27 08:10 |
| Citation |
Goyal O, Chowdhary R, Sehgal T, Joshi T, Bhambri A, Rampurawala IM, Sohi GS, Das A, Arora K, Vuthaluru AR, Goyal MK. Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders. World J Gastrointest Pharmacol Ther 2026; 17(2): 118616
|
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i2/118616.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v17.i2.118616 |
